The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

Kaat Spoormans; Lara Struelens; Koen Vermeulen; Marijke De Saint-Hubert; Michel Koole; Melissa Crabbé

The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

Kaat Spoormans, Lara Struelens, Koen Vermeulen, Marijke De Saint-Hubert, Michel Koole, Melissa Crabbé

Research output › peer-review

114 Downloads (Pure)

Abstract

Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, we
performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

Original language	English
Title of host publication	EANM’24 Abstract Book
Publisher	EANM - European Association of Nuclear Medicine
Chapter	205
Number of pages	1
Edition	2024
State	Published - 2024

Access to Document

s00259-024-06838-zFinal published version, 21.4 MBLicense: Unspecified

Cite this

@inproceedings{62fdb183892c448590c412eabd0439a4,

title = "The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists",

abstract = "Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.",

keywords = "177Lu-DOTATATE, 161Tb-DOTATATE, Peptide receptor radionuclide therapy, PRRT",

author = "Kaat Spoormans and Lara Struelens and Koen Vermeulen and {De Saint-Hubert}, Marijke and Michel Koole and Melissa Crabb{\'e}",

note = "Score=3",

year = "2024",

language = "English",

booktitle = "EANM{\textquoteright}24 Abstract Book",

publisher = "EANM - European Association of Nuclear Medicine",

address = "Austria",

edition = "2024",

}

TY - GEN

T1 - The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

AU - Spoormans, Kaat

AU - Struelens, Lara

AU - Vermeulen, Koen

AU - De Saint-Hubert, Marijke

AU - Koole, Michel

AU - Crabbé, Melissa

N1 - Score=3

PY - 2024

Y1 - 2024

N2 - Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

AB - Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

KW - 177Lu-DOTATATE

KW - 161Tb-DOTATATE

KW - Peptide receptor radionuclide therapy

KW - PRRT

M3 - In-proceedings paper

BT - EANM’24 Abstract Book

PB - EANM - European Association of Nuclear Medicine

ER -